Bayer Must Study Side Effects of Permanent Birth ControlBy
Adverse events include pelvic pain and uterus perforation
FDA recommends a boxed warning for sterilization devices
Bayer AG must do a study of its permanent birth control device Essure while it’s on the market to help better understand the potential risks to users, the Food and Drug Administration said Monday.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.